Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:IMUCNASDAQ:OTLKNASDAQ:RPTXNASDAQ:SKYE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMUCEOM Pharmaceuticals$0.11$0.13$0.01▼$0.25$14.16M0.068,103 shs26 shsOTLKOutlook Therapeutics$1.75+4.5%$1.44$0.87▼$9.25$56.03M0.39750,721 shs320,920 shsRPTXRepare Therapeutics$1.34+0.8%$1.17$0.89▼$4.29$57.47M0.85260,747 shs181,449 shsSKYESkye Bioscience$1.87-7.0%$1.81$1.14▼$12.77$57.92M1.74362,088 shs222,400 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMUCEOM Pharmaceuticals0.00%+6.37%-19.38%-29.13%-46.71%OTLKOutlook Therapeutics+4.48%+14.01%+27.74%-6.42%-76.45%RPTXRepare Therapeutics+0.75%-0.74%+16.52%+5.51%-62.46%SKYESkye Bioscience-6.72%-1.42%+12.95%-40.76%-85.21%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMUCEOM PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AOTLKOutlook Therapeutics1.8605 of 5 stars3.43.00.00.02.00.00.6RPTXRepare Therapeutics2.9717 of 5 stars3.35.00.00.01.92.50.6SKYESkye Bioscience1.3092 of 5 stars3.51.00.00.02.70.00.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMUCEOM Pharmaceuticals 0.00N/AN/AN/AOTLKOutlook Therapeutics 2.80Moderate Buy$10.20482.86% UpsideRPTXRepare Therapeutics 2.50Moderate Buy$4.50235.82% UpsideSKYESkye Bioscience 3.00Buy$16.60787.70% UpsideCurrent Analyst Ratings BreakdownLatest IMUC, SKYE, OTLK, and RPTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/21/2025SKYESkye BioscienceCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $14.003/21/2025SKYESkye BioscienceWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform3/7/2025RPTXRepare TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $5.002/28/2025SKYESkye BioscienceWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform2/24/2025OTLKOutlook TherapeuticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$33.00 ➝ $24.002/18/2025OTLKOutlook TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$3.00 ➝ $3.002/18/2025OTLKOutlook TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $3.00(Data available from 5/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMUCEOM PharmaceuticalsN/AN/AN/AN/AN/AN/AOTLKOutlook TherapeuticsN/AN/AN/AN/A($1.57) per shareN/ARPTXRepare Therapeutics$53.48M1.07N/AN/A$5.03 per share0.27SKYESkye BioscienceN/AN/AN/AN/A($0.17) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMUCEOM Pharmaceuticals-$1.61MN/A0.00∞N/AN/AN/AN/AN/AOTLKOutlook Therapeutics-$75.37M-$7.42N/AN/AN/AN/AN/A-225.12%5/21/2025 (Estimated)RPTXRepare Therapeutics-$93.80M-$2.00N/AN/AN/A-99.76%-40.87%-35.07%N/ASKYESkye Bioscience-$37.65M-$0.82N/AN/AN/AN/A-45.78%-37.44%N/ALatest IMUC, SKYE, OTLK, and RPTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q2 2025OTLKOutlook Therapeutics-$0.55-$0.40+$0.15-$1.50$0.70 millionN/A5/8/2025Q1 2025SKYESkye Bioscience-$0.31-$0.28+$0.03-$0.28N/AN/A3/20/2025Q4 2024SKYESkye Bioscience-$0.30-$0.24+$0.06-$0.24N/AN/A3/3/2025Q4 2024RPTXRepare Therapeutics-$0.77-$0.67+$0.10-$0.67$0.67 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMUCEOM PharmaceuticalsN/AN/AN/AN/AN/AOTLKOutlook TherapeuticsN/AN/AN/AN/AN/ARPTXRepare TherapeuticsN/AN/AN/AN/AN/ASKYESkye BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMUCEOM PharmaceuticalsN/AN/AN/AOTLKOutlook TherapeuticsN/A0.320.64RPTXRepare TherapeuticsN/A6.456.45SKYESkye BioscienceN/A14.1914.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMUCEOM PharmaceuticalsN/AOTLKOutlook Therapeutics11.20%RPTXRepare Therapeutics85.09%SKYESkye Bioscience21.09%Insider OwnershipCompanyInsider OwnershipIMUCEOM Pharmaceuticals3.28%OTLKOutlook Therapeutics4.80%RPTXRepare Therapeutics11.50%SKYESkye Bioscience4.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMUCEOM Pharmaceuticals3126.50 million122.35 millionNot OptionableOTLKOutlook Therapeutics2032.02 million30.48 millionOptionableRPTXRepare Therapeutics18042.89 million33.33 millionOptionableSKYESkye Bioscience1130.98 million29.43 millionOptionableIMUC, SKYE, OTLK, and RPTX HeadlinesRecent News About These CompaniesSkye Bioscience, Inc. (NASDAQ:SKYE) Receives Consensus Rating of "Buy" from AnalystsMay 16 at 3:14 AM | marketbeat.comSkye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 13, 2025 | globenewswire.comSkye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on ObesityMay 13, 2025 | globenewswire.comZepbound and Wegovy Go Head to Head for Obesity: And the Winner Is ...May 12, 2025 | medpagetoday.comSkye Bioscience (NASDAQ:SKYE) Issues Quarterly Earnings ResultsMay 12, 2025 | marketbeat.comEarnings call transcript: Skye Bioscience Reports Q1 2025 Financials Amid R&D ExpansionMay 10, 2025 | investing.comSkye Bioscience, Inc. (SKYE) Q1 2025 Earnings Call TranscriptMay 9, 2025 | seekingalpha.comSkye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in ObesityMay 8, 2025 | globenewswire.comBraidwell LP Buys Shares of 825,732 Skye Bioscience, Inc. (NASDAQ:SKYE)May 8, 2025 | marketbeat.comSkye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025May 7, 2025 | globenewswire.comWhy Skye Bioscience, Inc.’s (SKYE) Stock Is Down 5.53%May 7, 2025 | aaii.comSchonfeld Strategic Advisors LLC Acquires 463,644 Shares of Skye Bioscience, Inc. (NASDAQ:SKYE)May 6, 2025 | marketbeat.comSkye Bioscience to Participate in May Investment and Medical ConferencesApril 29, 2025 | globenewswire.comSkye Bioscience announces inducement grant under Nasdaq listing ruleApril 28, 2025 | markets.businessinsider.comSkye Bioscience Inc.April 26, 2025 | barrons.comSkye Bioscience Grants Stock Options to New Employee Under 2024 Inducement Equity Incentive PlanApril 25, 2025 | quiverquant.comSkye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)April 25, 2025 | globenewswire.comRx Rundown: Merck, the CDC, GSK and moreApril 18, 2025 | mmm-online.comWilliam Blair Predicts Skye Bioscience Q2 EarningsApril 18, 2025 | marketbeat.comA Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash ValueApril 16, 2025 | seekingalpha.comSkye Bioscience announces new preclinical data for nimacimabApril 15, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMUC, SKYE, OTLK, and RPTX Company DescriptionsEOM Pharmaceuticals OTCMKTS:IMUC$0.11 0.00 (0.00%) As of 05/16/2025Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.Outlook Therapeutics NASDAQ:OTLK$1.75 +0.08 (+4.48%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$1.78 +0.03 (+1.71%) As of 05/16/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.Repare Therapeutics NASDAQ:RPTX$1.34 +0.01 (+0.75%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$1.36 +0.02 (+1.42%) As of 05/16/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.Skye Bioscience NASDAQ:SKYE$1.87 -0.14 (-6.97%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$1.90 +0.03 (+1.39%) As of 05/16/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/12 - 05/16 Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Plug Power: Is Q1 Noise An Opportunity for Accumulation? Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
